Preliminary Program
(April 5, 2016)

Vaccine Technology VI

June 12-17, 2016

Grande Real Santa Eulalia Hotel
Albufeira, Portugal

Conference Co-Chairs

Laura A. Palomares
(UNAM, Mexico)

Tarit Mukhopadhyay
(University College London, UK)

Manon Cox
(Protein Sciences Corporation, USA)

Nathalie Garçon
(BIOASTER Technology Research Institute, France)
Vaccines: Reaching for higher branches after the low hanging fruit has been picked
Michael Kurilla, National Institute of Allergy and Infectious Diseases (NIAID), USA

TBD
Ian Frazer, University of Queensland, Australia

TBD
Johan Van Hoof, Janssen Research and Development, Belgium

TBD
Katey Owen, Bill & Melinda Gates Foundation, USA
Organizing Committee

Paula Alves, IBET
Rick Bright, BARDA
Barry Buckland, BiologicB
Fred Cassels, NIAID
Jose A. Chabelgoity, Instituto de Higiene
Anne de Groot, EpiVax
Monica Dias Figuereido, Merial
Francesc Godia, UABcelona
Johan Van Hoof, Janssen (J&J)
Amine Kamen, McGill University
Florian Krammer, Icahn School of Medicine at Mount Sinai
Linda Lua, University of Queensland
Charles Lutsch, Sanofi/Shanta
Bob Nordgren, Merial
Al Price, Medimmune
Hari Pujar, Moderna Therapeutics
Udo Reichl, Max Planck Institute
Guus Rimmelzwaan, Rotterdam University
Steve Rockman, CSL
Ingrid Scully, Pfizer
Rebecca Sheets, Grimalkin Partners
Sergio Valentinotti, Liomont
Vidadi Yusibov, Fraunhofer
Sunday, June 12, 2016

16:00 - 18:30  Conference check-in

18:30 - 19:30  Opening Keynote

19:30 - 21:00  Dinner
Monday, June 13, 2016

07:30 - 08:30  Breakfast buffet

08:30 – 10:30  Session I: Break Through Developments in Vaccinology
Chairs: Florian Krammer, The Mount Sinai Hospital, USA, and Hari Pujar, Moderna Therapeutics, USA

Applications of high-throughput single B-cell sequencing to accelerate rational vaccine design
Brandon J. DeKosky, Vaccine Research Center / NIAID, USA

Single-cell analysis of Influenza A virus-infected cells for the optimization of cell culture-based vaccine production
Sascha Young Kupke, Max Planck Institute for Dynamics of Complex Technical Systems, Germany

Development of Typhax, a Salmonella Typhi Vi polysaccharide protein capsular matrix vaccine
Kevin P. Killeen, Matrivax R&D Corp, USA

A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in ferrets
Raffael Nachbagauer, Icahn School of Medicine at Mount Sinai, USA

10:30 - 11:00  Coffee break

11:00 – 13:00  Session II: Issues and Case Studies in Process Development
Chairs: Udo Reichl, Max Planck, Germany and Charles Lutsch, Shantha Biologics, India

Upstream and downstream process development of a Vero cell-based yellow fever vaccine
Leda R. Castilho, Federal University of Rio de Janeiro (UFRJ), Brazil

Fast-track lentiviral vector upstream process development: leveraging high-throughput process monitoring, single-use bioreactor scalability
Nicolas Sève, Sanofi Pasteur, France

A live attenuated RSV vaccine, process development studies
Yvonne E. Thomassen, Intravacc, Netherlands

Hollow fiber-based high-cell-density and two-stage bioreactor continuous cultivation: Options and limits towards process intensification for virus production
Yvonne Genzel, Max Planck Institute for Dynamics of Complex Technical Systems, Germany

13:00 - 14:00  Lunch

14:00 - 15:30  Workshop I: Are regulatory hurdles limiting vaccine manufacturing innovation?
Facilitators: Katey Owen, The Bill and Melinda Gates Foundation, USA and David Robinson, Robinson Vaccines and Biologics LLC, USA
Monday, June 13, 2016 (continued)

15:30 - 16:00  
Ad hoc discussions/networking time

16:00 - 18:00  
**Session III: Formulating and Delivering Vaccines**  
Chair: David Volkin, University of Kansas, USA

- **Adjuvants in preclinical and clinical development: the do and don’t**  
  Nathalie Garçon, BIOASTER Technology Research Institute, France

- **Combining DOE with an empirical approach to improve vaccine formulation development**  
  Jill Livengood, Takeda, USA

- **Development of a thermostable ID93 + GLA-SE vaccine using a design of experiments (DOE) approach**  
  Ryan M. Kramer, Infectious Disease Research Institute (non-profit), USA

- **Controlled, pulsatile release of thermostabilized inactivated polio vaccine from PLGA-based microspheres**  
  Stephany Y. Tzeng, Massachusetts Institute of Technology, USA

18:30 - 20:30  
Dinner

20:30 - 22:00  
**Poster Session I with Social Hour**  
Chairs: Valerie Mermall, Protein Sciences, USA, Ruth Pastor, UNAM, Mexico, Antonio Roldao, IBET, Portugal
Tuesday, June 14, 2016

07:30 - 08:30  Breakfast buffet

8:30 – 10:30  **Session V: Therapeutic Vaccines**  
Chairs: Laurent Humseau, Inovio, USA, and Tony Hitchcock, Cobra Biologics, UK

- **Current technologies for advancing HIV vaccines**  
  Vadim Tsvetnitsky, IAVI, USA

- TBD  
  David Wiener, University of Pennsylvania, USA

10:30 - 11:00  Coffee break

11:00 - 12:00  **Keynote lecture**

12:00 - 13:30  **Workshop II: Academy-Industry Interactions for Advancing in Vaccine Development**  
Facilitators: Alex Xenopoulos, EMD Millipore, USA and Manuel JT Carrondo, IBET, Portugal

14:00 - 19:30  Pick up boxed lunch

- Boat excursion and guided tour of Faro

19:30 - onwards  Dinner on your own
Wednesday, June 15, 2016

07:30 - 08:30  Breakfast buffet

8:30 - 10:30  **Session VI: Getting Vaccines to the Market: Case studies**
Chair: Rebecca Sheets, Grimalkin Partners, USA and Danilo Casimiro, Merck, USA

- **RSV vaccines for the young and the old**
  Albert E. Price, MedImmune, USA

- **Development, manufacturing, and supply of Merck’s Ebola vaccine**
  Jeffrey T. Blue, Merck & Co. Inc., USA

- **Third generation vaccine for world eradication of poliomyelitis**
  Emilie Rodrigues, Intravacc, Netherlands

  TBD

10:30 - 11:00  Coffee break

11:00 - 12:30 **Workshop III. Vaccine Design and Evaluation - The iVAX Toolkit**
Facilitator: Frances Terry, EpiVax, USA

12:30 - 13:00  Ad hoc discussions / networking

13:00 - 14:00  Lunch

14:00 - 16:00  Ad hoc discussions / networking

16:00 – 17:00  **Session II: Issues and Case Studies in Process Development**
Chair: Udo Reichl, Max Planck, Germany and Charles Lutsch, Shantha Biologics, India

- **Genetic engineering of vaccine manufacturing cell lines enhances poliovirus and enterovirus 71 production**
  Jon M. Karpilow, Proventus Bio, USA

- **Determining whether adsorption state is a critical attribute in aluminum adjuvanted vaccines**
  Garry Morefield, VaxForm, USA

- **Challenges in the development and scale-up of a purification process for an attenuated live virus vaccine candidate**
  Matthew Woodling, Merck & Co., Inc., USA

17:00 - 18:00  **Keynote lecture**

18:30 - 20:00  Dinner

20:30 - 22:30  **Poster session II and Social Hour**
Chairs: Valerie Mermall, Protein Sciences, USA, Ruth Pastor, UNAM, Mexico, Antonio Roldao, IBET, Portugal
Thursday, June 16, 2016

07:30 - 08:30  Breakfast buffet

8:30 – 10:30  **Session IV: Vaccine Characterization and Analytics**
Chairs: Linda Lua, University of Queensland, Australia, and Indresh Srivastava, Protein Sciences, USA

Multi-tasking an inactivated influenza vaccine to provide rapid innate immune-system mediated protection and subsequent long-term adaptive immunity against influenza and secondary pneumococcal infections
Brendon Y. Chua, The University of Melbourne, Australia

How does the addition of surface protein antigens to a potential vaccine for *Staphylococcus aureus* affect the immune response it induces?
Christopher D. Dupont, Massachusetts Institute of Technology, USA

Correlations of antibody response phenotype to genotype revealed by molecular amplification fingerprinting
Sai Reddy, ETH Zurich, Switzerland

TBD

Universal and in-process analytical tool for Influenza quantification using a label-free technology
Sofia Carvalho, iBET/ITQB, Portugal

10:30 - 11:00  Coffee break

11:00 - 13:00  **Session VII: New Challenges and Technologies in Vaccine Development**
Chairs: Albert Price, MedImmune, USA and Odile Leroy, European Vaccine Initiative

TBD
John Tsang, NIAID, USA

Induction of antigen-specific immune tolerance with synthetic nanoparticle vaccines
Takashi Kei Kishimoto, Selecta Biosciences, USA

Immune engineering enhances H7N9 vaccine immunogenicity by regulatory T cell epitope deletion in hemagglutinin
Annie De Groot, EpiVax, Inc., Institute for Immunology and Informatics, University of Rhode Island, USA

Plant-based technologies to enable rapid response to Ebola outbreak
Jerzy Karczewski & Vidadi Yusibov, Fraunhofer USA.

13:00 - 15:00  **Poster session I and II with Grazing Lunch**
Chairs: Valerie Mermall, Protein Sciences Corporation, USA, Ruth Pastor, UNAM, Mexico, Antonio Roldao, IBET, Portugal

15:00 - 16:00  Ad hoc discussions / Networking
Thursday, June 16, 2016 (continued)

16:00 – 18:00

**Session VIII. One World, One Health**

**Chairs:** Jean-Christophe Audonnet, Merial, France, Juan Garza, UNAM, Ab Osterhaus, University of Veterinary Medicine Hannover, Germany,

TBD

Bernard Vallat, OIE

**Structural-based designed modular capsomere comprising HA1 as low-cost poultry influenza vaccine**

Jarurin Waneesorn, The University of Queensland, Australia

**Development of a vaccine based on recombinant subunit proteins to protect humans and animals against filovirus disease**

Axel T. Lehrer, University of Hawaii, USA

TBD

18:30 - 19:00

Coffee break

19:00 - 20:00

**Closing keynote**

Katey Owen, Deputy Director, Vaccines Development CMC, The Bill and Melinda Gates Foundation

20:00 - 22:00

Conference Banquet
Friday, June 17, 2016

07:30 - 09:00  Breakfast Buffet

Departures